金吾财讯 | 威高股份(01066)公布，截至2024年12月31日止年度，公司拥有人应占溢利20.67亿元(人民币，下同)，同比增长3.24%；每股基本盈利0.46元。拟派末期股息每股0.1235元。期内，集团收入130.87亿元，同比减少1.08%；毛利65.81亿元，同比减少0.94%。毛利率50.3%，同比微增0.1个百分点。期内，集团医疗器械产品业务录得营业额约62.97亿元，同比下降6.4%；药品包装业务录得营业额约22.79亿元，同比增长12.6%；骨科业务营业额约为14.39亿元，同比增长13.2%；介入业务录得营业额约21.96亿元，同比增长1.4%。截至2024年12月31日止年度，集团中国国内新取得产品注册证150项，已经研发完成、尚在取证过程中的有44项；新获得专利127项，正在申请中的147项。截至2024年12月31日止年度，集团国内拥有逾873项产品注册证，1,040项专利，其中198项是发明专利。期内，集团研发之总开支约为6.25亿元，占集团收入的4.8%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.